You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | n/a |
| Div Cover | n/a | n/a |
| Op Mrgn | -95.6% | n/a |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -5.8 | n/a |
| PEG | 0.0 | n/a |
| Price / Revenue | 5.1 | n/a |
| Price / Book value | 3.4 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 11,761.9% | 11.5% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 44.1% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | 214.11 | -86.65 | $-0.01 | -405.6 | 0.0 | n/a | n/a | 0.0% |
| 2019-12-31 | 204.89 | -141.10 | $-0.16 | -31.5 | 0.0 | n/a | n/a | 0.0% |
| 2020-12-31 | 227.98 | -189.73 | $-0.18 | -34.9 | 0.0 | n/a | n/a | 0.0% |
| 2021-12-31 | 356.13 | -215.74 | $0.00 | -2,840.3 | 0.0 | n/a | n/a | 0.0% |
| 2022-12-31 | 426.41 | -410.42 | $-0.43 | -7.4 | 0.0 | n/a | n/a | 0.0% |
| US FDA gives priority to Hutchmed's colorectal cancer treatment Sharecast News | 26 May |
|---|---|
| Hutchmed's gastric cancer treatment accepted for review in China Sharecast News | 18 Apr |
| Hutchmed completes rolling FDA submission for colorectal cancer drug Sharecast News | 31 Mar |
| Total Voting Rights | 31-May-23 17:49 |
|---|---|
| Fruquintinib NDA Granted Priority Review by FDA | 26-May-23 14:24 |
| Standard form for notification of major holdings | 17-May-23 17:57 |
| Annual General Meeting Poll Results | 12-May-23 22:09 |
| Board of Directors and Board Committee Membership | 12-May-23 17:34 |